Payment overview · 2025
General Payments
$1,475.06
52 reported records · 18 companies
Healthcare provider profile · identity verified
Sergio Hernandez Borges
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI LAKES, FL · NPI 1043600414
Verified facts
What the public records show
CMS Open Payments records show Sergio Hernandez Borges received $1,475.06 in general payments during 2025 across 52 reported records.
Corcept Therapeutics accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $239.55 | 16.2% | 6 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $167.37 | 11.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $161.28 | 10.9% | 8 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $150.71 | 10.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $121.65 | 8.2% | 6 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $90.96 | 6.2% | 5 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $80.99 | 5.5% | 4 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $72.44 | 4.9% | 3 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.32 | 4.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.26 | 4.4% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $64.89 | 4.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.64 | 3.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.10 | 2.4% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $29.39 | 2.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $23.96 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.14 | 1.4% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $18.93 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.48 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,475.06 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $239.55 | 6 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $167.37 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $150.71 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $150.71 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $150.71 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $121.65 | 6 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $99.78 | 5 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $90.96 | 5 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $80.99 | 4 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $69.32 | 3 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $64.89 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $61.50 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.99 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.64 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $29.39 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 737 | 144 |
| Eliquis | Apixaban | 552 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 96 |
| Metformin Hcl | Metformin Hcl | 405 | 60 |
| Gabapentin | Gabapentin | 342 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 296 | 48 |
| Levetiracetam | Levetiracetam | 286 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 59 |
| Furosemide | Furosemide | 276 | 73 |
| Losartan Potassium | Losartan Potassium | 276 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 274 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 55 |
| Lisinopril | Lisinopril | 258 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 55 |
| Famotidine | Famotidine | 222 | 52 |
| Baclofen | Baclofen | 203 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 60 |
| Carvedilol | Carvedilol | 181 | 37 |
| Latanoprost | Latanoprost | 181 | 33 |
| Nifedipine Er | Nifedipine | 152 | 38 |
| Omeprazole | Omeprazole | 145 | 36 |
| Mirtazapine | Mirtazapine | 143 | 40 |
| Gemtesa | Vibegron | 140 | suppressed |
| Lactulose | Lactulose | 140 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 130 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 128 | 30 |
| Trazodone Hcl | Trazodone Hcl | 128 | 42 |
| Donepezil Hcl | Donepezil Hcl | 124 | 26 |
| Allopurinol | Allopurinol | 123 | 22 |
| Montelukast Sodium | Montelukast Sodium | 121 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 18 |
| Xarelto | Rivaroxaban | 113 | 19 |
| Sertraline Hcl | Sertraline Hcl | 110 | 32 |
| Glipizide | Glipizide | 107 | 19 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 107 | 18 |
| Simvastatin | Simvastatin | 101 | 15 |
| Memantine Hcl | Memantine Hcl | 100 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 32 |
| Finasteride | Finasteride | 97 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 96 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 90 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 81 | 16 |
| Spironolactone | Spironolactone | 81 | 19 |
| Albuterol Sulfate | Albuterol Sulfate | 79 | 16 |
| Midodrine Hcl | Midodrine Hcl | 74 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 71 | 20 |
| Lubiprostone | Lubiprostone | 68 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 67 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 65 | 20 |
| Buspirone Hcl | Buspirone Hcl | 60 | 14 |
| Entresto | Sacubitril/Valsartan | 59 | 12 |
| Potassium Chloride | Potassium Chloride | 58 | 15 |
| Timolol Maleate | Timolol Maleate | 58 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Ketoconazole | Ketoconazole | 51 | 15 |
| Divalproex Sodium | Divalproex Sodium | 50 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | 17 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Meloxicam | Meloxicam | 49 | 13 |
| Novolog Flexpen | Insulin Aspart | 48 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 47 | suppressed |
| Lacosamide | Lacosamide | 47 | suppressed |
| Jardiance | Empagliflozin | 46 | suppressed |
| Levofloxacin | Levofloxacin | 46 | 35 |
| Folic Acid | Folic Acid | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 17 |
| Prednisone | Prednisone | 43 | 21 |
| Bumetanide | Bumetanide | 42 | 12 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 39 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 13 |
| Sodium Chloride | 0.9 % Sodium Chloride | 34 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 18 |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 30 |
| Risperidone Odt | Risperidone | 32 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 28 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 27 | 13 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Risperidone | Risperidone | 26 | 12 |
| Azithromycin | Azithromycin | 25 | 21 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Nystatin | Nystatin | 25 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Meropenem | Meropenem | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Vancomycin Hcl | Vancomycin Hcl | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Fiasp | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Phenytoin | Phenytoin | 16 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Ceftazidime | Ceftazidime | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Renvela | Sevelamer Carbonate | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,475.06 · 52 records | Corcept Therapeutics | AFREZZA, CeQur Simplicity, Dexcom G6 Transmitter, ENTRESTO, EVENITY, GVOKE HYPOPEN, ISTURISA, Kerendia, Korlym, LEQVIO, MOUNJARO, RECORLEV, REZDIFFRA, TEPEZZA, TRYNGOLZA, TWIIST, TZIELD, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error